Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | The comparative effectiveness of natalizumab and ocrelizumab in naïve relapsing remitting MS

Pietro Iaffaldano, MD, The University of Bari Aldo Moro, Bari, Italy, explores a comparative study of natalizumab and ocrelizumab in naïve relapsing-remitting multiple sclerosis (MS) to understand their effectiveness in suppressing relapse activity. Both treatment groups showcased a notable absence of relapse events, emphasizing the efficacy of both drugs in mitigating relapse activity. The study involved balanced groups with 195 patients in each, observed for approximately two years. The primary focus was on progression independent of relapse activity. While both drugs effectively combatted relapse, there was no significant statistical difference between them concerning the first progression events. Thus, neither drug can be conclusively deemed superior. Prof. Iaffaldano emphasizes that the choice between these two drugs should hinge on individual clinical characteristics, patient preferences, safety profiles, and considerations such as family planning. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.